Researchers developed a combinatorial nanomedicine comprising abiraterone and enzalutamide bioconjugated survivin-encapsulated gold nanoparticles for targeted therapy of prostate cancer.
[European Journal of Pharmaceutics and Biopharmaceutics]
Survivin-Targeted Nanomedicine for Increased Potency of Abiraterone and Enzalutamide Against Prostate Cancer
